Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial

Jessica M Scott, Samantha M Thomas, Jeffrey M Peppercorn, James E Herndon 2nd, Pamela S Douglas, Michel G Khouri, Chau T Dang, Anthony F Yu, Diane Catalina, Cristi Ciolino, Catherine Capaci, Meghan G Michalski, Neil D Eves, Lee W Jones, Jessica M Scott, Samantha M Thomas, Jeffrey M Peppercorn, James E Herndon 2nd, Pamela S Douglas, Michel G Khouri, Chau T Dang, Anthony F Yu, Diane Catalina, Cristi Ciolino, Catherine Capaci, Meghan G Michalski, Neil D Eves, Lee W Jones

Abstract

Background: Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise programming that has received minimal attention is dose scheduling. We investigated the tolerability and efficacy of 2 exercise training dose regimens on cardiorespiratory fitness and patient-reported outcomes in patients with posttreatment primary breast cancer.

Methods: Using a parallel-group randomized trial, we randomly allocated 174 postmenopausal patients (2.8 years after adjuvant therapy) with impaired peak oxygen consumption (VO2peak) to 1 of 2 supervised exercise training interventions delivered with a standard linear (LET) (fixed dose intensity per session for 160 min/wk) or nonlinear (NLET) (variable dose intensity per session for ≈120 min/wk) schedule compared with a stretching attention control group for 16 consecutive weeks. Stretching was matched to exercise dosing arms on the basis of location, frequency, duration, and treatment length. The primary end point was change in VO2peak (mL O2·kg-1·min-1) from baseline to after intervention. Secondary end points were patient-reported outcomes, tolerability, and safety.

Results: No serious adverse events were observed. Mean attendance was 64%, 75%, and 80% for attention control, LET, and NLET, respectively. In intention-to-treat analysis, VO2peak increased 0.6±1.7 mL O2·kg-1·min-1 (P=0.05) and 0.8±1.8 mL O2·kg-1·min-1 (P=0.07) in LET and NLET, respectively, compared with attention control. Change in VO2peak ranged from -2.7 to 4.1 mL O2·kg-1·min-1 and from -3.6 to 5.1 mL O2·kg-1·min-1 in LET and NLET, respectively. Approximately 40% of patients in both exercise dosing regimens were classified as VO2peak responders (ie, Δ ≥1.32 mL O2·kg-1·min-1). NLET improved all patient-reported outcomes compared with attention control.

Conclusions: Short-term exercise training, independently of dosing schedule, is associated with modest improvements in cardiorespiratory fitness in patients previously treated for early-stage breast cancer.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01186367.

Keywords: breast neoplasms; cardiorespiratory fitness; exercise.

Figures

Figure 1.
Figure 1.
Planned intensity and duration of each individual session (i.e., dose) as well as the schedule of treatment dose across the study intervention period for (A) linear dosing and (B) non-linear dosing. The planned prescription depicts the intensity, duration, and scheduling of sessions under the assumption that no sessions were missed or dose modified, as per protocol. All doses were individualized to each patient on the basis of the pre-randomization cardiopulmonary exercise test (CPET). In the non-linear arm, at the end of week 8 the CPET was repeated to re-prescribe exercise intensity (green bar). The intensity of each session depicted by the colored bars as a percentage of VO2peak: (1) black – 55%, (2) blue – 65%, (3) orange – 70% to 75%, (4) grey – 85%, and (5) red – >95%. Black dots depict the planned duration of each session (mins), ranging from a minimum of 20 mins/session to a maximum of 45 mins/session. VO2peak, peak oxygen consumption.
Figure 1.
Figure 1.
Planned intensity and duration of each individual session (i.e., dose) as well as the schedule of treatment dose across the study intervention period for (A) linear dosing and (B) non-linear dosing. The planned prescription depicts the intensity, duration, and scheduling of sessions under the assumption that no sessions were missed or dose modified, as per protocol. All doses were individualized to each patient on the basis of the pre-randomization cardiopulmonary exercise test (CPET). In the non-linear arm, at the end of week 8 the CPET was repeated to re-prescribe exercise intensity (green bar). The intensity of each session depicted by the colored bars as a percentage of VO2peak: (1) black – 55%, (2) blue – 65%, (3) orange – 70% to 75%, (4) grey – 85%, and (5) red – >95%. Black dots depict the planned duration of each session (mins), ranging from a minimum of 20 mins/session to a maximum of 45 mins/session. VO2peak, peak oxygen consumption.
Figure 2.
Figure 2.
CONSORT Flow for Non-Pharmacological Trials.
Figure 3.
Figure 3.
Waterfall plots for change in VO2peak. The technical error (TE) for VO2peak (Δ1.32 mL O2·kg−1·min−1) is illustrated by the shaded area. Patients with a change in VO2peak greater than TE classified as responders. Black bars: attention control; grey bars: standard linear exercise training; blue bars: non-linear exercise training. VO2peak, peak oxygen consumption.

References

    1. Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, Hornsby WE, Coan AD, Herndon JE 2nd, Douglas PS, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012;30:2530–2537.
    1. Koelwyn GJ, Jones LW and Moslehi J. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. J Am Coll Cardiol. 2014;64:1320–1322.
    1. Cupit-Link MC, Kirkland JL, Ness KK, Armstrong GT, Tchkonia T, LeBrasseur NK, Armenian SH, Ruddy KJ and Hashmi SK. Biology of premature ageing in survivors of cancer. ESMO Open. 2017;2:e000250.
    1. Scott JM, Dolan LB, Norton L, Charles JB and Jones LW. Multisystem Toxicity in Cancer: Lessons from NASA’s Countermeasures Program. Cell. 2019;179:1003–1009.
    1. Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, Grobbee DE and Verkooijen HM. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164:537–555.
    1. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS and Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435–1441.
    1. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, Moskowitz CS, Matsoukas K, Iyengar NM, Dang CT, et al. Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2018;36:2297–2305.
    1. Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, McCarthy S, Murnane A, Patchell S and Adams D. Clinical Oncology Society of Australia position statement on exercise in cancer care. Med J Aust. 2018;209:184–187.
    1. Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, et al. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2018;16:1216–1247.
    1. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019;51:2375–2390.
    1. Fitzgerald MD, Tanaka H, Tran ZV and Seals DR. Age-related declines in maximal aerobic capacity in regularly exercising vs. sedentary women: a meta-analysis. J Appl Physiol. 1997;83:160–165.
    1. American Thoracic S and American College of Chest P. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211–277.
    1. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, et al. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1140–1163.
    1. Seiler KS and Kjerland GO. Quantifying training intensity distribution in elite endurance athletes: is there evidence for an “optimal” distribution? Scand J Med Sci Sports. 2006;16:49–56.
    1. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J and Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015;6:115–124.
    1. Nilsen TS, Scott JM, Michalski M, Capaci C, Thomas S, Herndon JE 2nd, Sasso J, Eves ND and Jones LW. Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis. Med Sci Sports Exerc. 2018;50:1134–1141.
    1. Scott JM, Iyengar NM, Nilsen TS, Michalski M, Thomas SM, Herndon J 2nd, Sasso J, Yu A, Chandarlapaty S, Dang CT, et al. Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. Cancer. 2018;124:2552–2560.
    1. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, et al. Clinician’s Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:191–225.
    1. ATS/ACCP. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211–277.
    1. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M and Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–986.
    1. Lai JS, Cella D, Chang CH, Bode RK and Heinemann AW. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res. 2003;12:485–501.
    1. Godin G and Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985;10:141–146.
    1. Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ and Mackey JR. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007;16:1026–1031.
    1. Jones LW, Haykowsky M, Pituskin EN, Jendzjowsky NG, Tomczak CR, Haennel RG and Mackey JR. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer. Oncologist. 2007;12:1156–1164.
    1. Ross R, de Lannoy L and Stotz PJ. Separate Effects of Intensity and Amount of Exercise on Interindividual Cardiorespiratory Fitness Response. Mayo Clin Proc. 2015;90:1506–1514.
    1. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–939.
    1. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ and Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003;21:1660–1668.
    1. Ellingsen O, Halle M, Conraads V, Stoylen A, Dalen H, Delagardelle C, Larsen AI, Hole T, Mezzani A, Van Craenenbroeck EM, et al. High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. Circulation. 2017;135:839–849.
    1. Haykowsky MJ, Timmons MP, Kruger C, McNeely M, Taylor DA and Clark AM. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013;111:1466–1469.
    1. Gomes-Neto M, Duraes AR, Reis H, Neves VR, Martinez BP and Carvalho VO. High-intensity interval training versus moderate-intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1696–1707.
    1. Scott JM, Nilsen TS, Gupta D and Jones LW. Exercise Therapy and Cardiovascular Toxicity in Cancer. Circulation. 2018;137:1176–1191.
    1. Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, Haskell WL, Kaminsky LA, Levine BD, Lavie CJ, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation. 2016;134:e653–e699.
    1. Leifer ES, Brawner CA, Fleg JL, Kraus WE, Whellan DJ, Pina IL and Keteyian SJ. Are there negative responders to exercise training among heart failure patients? Med Sci Sports Exerc. 2014;46:219–224.
    1. Jones LW, Hornsby WE, Freedland SJ, Lane A, West MJ, Moul JW, Ferrandino MN, Allen JD, Kenjale AA, Thomas SM, et al. Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. Eur Urol. 2014;65:852–855.
    1. Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M and Jones LW. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126:2749–2763.
    1. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998.
    1. Amir E, Seruga B, Niraula S, Carlsson L and Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–1309.
    1. Koelwyn GJ, Lewis NC, Ellard SL, Jones LW, Gelinas JC, Rolf JD, Melzer B, Thomas SM, Douglas PS, Khouri MG, et al. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. Oncologist. 2016;21:141–149.
    1. Beaudry RI, Howden EJ, Foulkes S, Bigaran A, Claus P, Haykowsky MJ and Gerche A. Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy. Physiol Rep. 2019;7:e13971.
    1. Gilliam LA and St Clair DK. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011;15:2543–2563.
    1. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015;163:1079–1094.
    1. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, Stewart C, Buchanan TA, Spicer D, Tripathy D, et al. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res. 2018;20:124.
    1. Topol EJ. A decade of digital medicine innovation. Sci Transl Med. 2019;11 DOI: 10.1126/scitranslmed.aaw7610.

Source: PubMed

3
Subscribe